Alok Saxena

Elder Pharma recently sold one of its key brands, Shelcal, to Torrent Pharma. Post the sale, Elder is focusing on remaining brands, including Eldervit and Somazina.

Looking at a turnover of Rs 200cr from domestic biz: Elder

In the long-term, Elder Pharma plans to bring products from the R&D pipeline, actively being worked on in the UK, and launch them in the Indian market, says Alok Saxena, Joint MD, Elder Pharma.

Elder Pharma weighs sale of nutrition business: Sources

Drugmaker Elder Pharmaceuticals is exploring options to sell its nutrition products business, two sources with direct knowledge of the development said.

Bullish on domestic market: Elder Pharma

In an interview to CNBC-TV18, Alok Saxena, joint managing director of Elder Pharma says, he is bullish on the domestic market. “On the domestic front, we are still growing at about 25%. All our brands are growing at 25%. This segment will continue to be the major growth driver for the company,” he adds.

Elder Pharma sees 21% growth in domestic formulations ahead

In an interview with CNBC-TV18, Alok Saxena, Director (International), Elder Pharmaceuticals spoke about the performance of the company. The company is expecting its domestic formulation business to report growth of 20-25% ahead.

Bulgarian facility to help jumpstart Elder Pharma's Shelcal into European market

Alok Saxena, director of Elder Pharma, in an interview with CNBC-TV18’s Latha Venkatesh and Anuj Singh, spoke about the recent happenings in his company and the road ahead.

Neutrahealth, euro arm to boost sales in Q4: Elder Pharma

In an exclusive interview with of Letha Venkatesh and Gautum Broker of CNBC TV 18`s Alok Saxena, Director, Elder Pharmaceuticals said, ``The company is seeing strong growth due to consolidation of Neutrahealth, Also, it is confident of getting positive turnover from Bulgaria in the next financial year.``

To buy 1-2% of $70 bn Japanese pharma mkt: Elder

Elder Pharmaceuticals recently received an accreditation from the Ministry of Health, Japan for their API plant in Maharashtra. In an exclusive interview with CNBC-TV18, Alok Saxena, Director of Elder Pharmaceuticals says that the accreditation is going to help enter grow in the Japanese pharma market.